Mechanistically, rapamycin reshaped the immunosuppressive TME by depleting α-SMA+ cancer-associated fibroblasts, degrading collagens, increasing the intratumoral infiltration of T cells, and decreasing PD-L1 expression in tumor cells. Here, CD274 is linked to neoplasm.